Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew T Hueman

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2008
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin, Linda C Benavides, Jarrod P Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patientsMatthew T Hueman, Zia A Dehqanzada, Thomas E Novak, et al.
Military Medicine|November 1, 2017
Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General PopulationYuanbin Ru, Jianfang Liu, J Leigh Fantacone-Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02George E Peoples, Jarrod P Holmes, Matthew T Hueman, et al.
Vaccine|September 23, 2010
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptideJeremy D Gates, Guy T Clifton, Linda C Benavides, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2008
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin, Linda C Benavides, Jarrod P Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patientsMatthew T Hueman, Zia A Dehqanzada, Thomas E Novak, et al.
Military Medicine|November 1, 2017
Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General PopulationYuanbin Ru, Jianfang Liu, J Leigh Fantacone-Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02George E Peoples, Jarrod P Holmes, Matthew T Hueman, et al.
Vaccine|September 23, 2010
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptideJeremy D Gates, Guy T Clifton, Linda C Benavides, et al.
Pageof 4